EGFR and cervical cancer: In a recent phase II trial reported by Goncalves et al, patients with recurring locoregionally advanced or metastatic cervical cancer were treated with gefitinib 500 mg/day, EGFR expression levels by means of immunohistochemistry did not correlate with tumor response and disease control [20].